The present disclosure provides antibody-drug conjugate (ADC) structures, which include a camptothecine or a camptothecine derivative linked to a polypeptide (e.g., an antibody) through a linker. The disclosure also encompasses compounds and methods for production of such conjugates, as well as methods of using the conjugates.

This invention relates to anti-CD70 antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are αCD70 antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the αCD70 antibodies of the invention are conjugated to one or more toxins. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, including therapeutic, diagnostic, and other biotechnology uses.

Provided is a conjugate of the formula (I) for treatment of tumors expressing PSMA, which comprises a PSMA-ligand with a linker and an antineoplastic agent monomethyl aluistatin E (MMAE). A composition for lyophilizate preparation based on the conjugate, a dosage form for therapy and obtained by the lyophilization of the composition, PSMA expressing a prostate tumor growth inhibition, a solution for infusions or injections containing the dosage form, reconstituted by a solvent, comprising 95% ethyl alcohol and polysorbate 80 at a mass ratio (30-60 wt %):(70-40 wt %), respectively, also provided. It is possible to obtain high affinity and selectivity of the action of the conjugates in relation to PSMA expressing cells using the conjugate of the formula (I).

Anti-lymphoma plant virus particles are described. The anti-lymphoma plant virus particles include a filamentous or rod-shaped plant virus particle linked to an antimitotic agent. A therapeutically effective amount of an anti-lymphoma plant virus particle can be administered to a subject to provide a method of treating lymphoma.

The present invention provides a compound having the structure of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, or isomer thereof, for the controlled delivery and release of Agent. ##STR00001##

The present disclosure provides antibody-drug conjugate (ADC) structures, which include a camptothecine or a camptothecine derivative linked to a polypeptide (e.g., an antibody) through a linker. The disclosure also encompasses compounds and methods for production of such conjugates, as well as methods of using the conjugates.

The present disclosure provides a method for photocleavage of an amide bond, the method has mild reaction conditions and can realize the cleavage of amide bonds by using light. The method comprises the following steps: subjecting 2,4-dinitrofluorobenzene to a reaction with an amino group of a substance represented by structural formula I with an α-amino acid at the end to produce a compound 1 represented by structural formula II; then under light irradiation, subjecting the compound 1 to a cleavage reaction of amide bond;

##STR00001##

Wherein, R1 is the side chain group of α-amino acid; R2 is: aryl, aliphatic hydrocarbon, —CH(R)—COOH or polypeptide.

The present disclosure relates to certain molecules, pharmaceutical compositions containing them, and methods of using them to treat viral infections.

Various embodiments provide a homo-bivalent linker compound comprising identical functional groups at either end, methods of making such linker compounds, and methods of using the linker compounds.

The present invention relates to a metal phase transformation compound and a method for preparing the same.